Introduction
E. coli PNP differs fundamentally from the HSVtk/ganciclovir system, since direct cell-to-cell contact or gap junctions are not required for E. coli PNP to kill cells. [1] [2] [3] [4] [5] The PNP enzyme cleaves MePdR to liberate 6-methyl purine, (MeP), a potent, membrane permeant and freely diffusible toxin. Strong bystander killing is a hallmark of this approach in human colon, melanoma, and glioma cancer cells in vitro. [1] [2] [3] [5] [6] [7] [8] [9] Furthermore, because MeP inhibits protein, RNA, and DNA synthesis, the compound kills both quiescent and proliferating tumor cells. 6 Tumor cell killing can be evoked in a specific fashion through tumor specific regulatory elements. 2, 3 In previous studies, a minimum of 200 nmol MePdR converted per milligram tumor cell extract per hour (or conversion units, CU) within a growing tumor was necessary in order to demonstrate complete regression of human tumors in animal models in vivo. Lower levels of E. coli PNP expression (40 to 60 CU) were shown to mediate ovarian tumors transfected with E. coli PNP were excised 5 days after i.p. implantation from the peritoneal cavities of mice in order to determine both E. coli PNP enzymatic activity and the fraction of cells expressing the gene. PNP activity at 5 days after gene transfer was approximately 170 CU and was expressed in approximately 0.1% of the tumor cells as judged by in situ hybridization. The expression of E. coli PNP at this level produced a 30% increase in life span (P Ͻ 0.001) and 49% reduction in tumor size (P Ͻ 0.005) after MeP-dR treatment, as compared with control tumors. Our observations lead to the conclusion that pronounced bystander killing by E. coli PNP is conferred in vivo, and that vectors capable of transgene expression in as few as one in 1000 cells can produce substantial antitumor effects if expression on a per cell basis is very high. Gene Therapy (2000) 7, 1738-1743. more modest antitumor effects. Tumor reductions and cures were elicited in mouse models of human cancer when 20-100% of tumor cells expressed E. coli PNP, without toxicity to the host. 4 However, no previous studies have evaluated in vivo bystander killing when fewer than one in 100 cells express the gene.
In the present study, we explore boundaries of bystander killing and elucidate an enzymatic surrogate that can be used to predict tumor responsiveness using E. coli PNP. We tested tumor cell killing by E. coli PNP in an ovarian tumor model in order to address the following questions. First, can high level transactivation be used to kill cells more effectively with E. coli PNP than with conventional promoter constructs? Second, will transfected cells implanted into a mouse express levels of the gene in vivo that might be suitable to mediate antitumor effects? Third, what level of intratumoral E. coli PNP expression is necessary to mediate at least some antitumor effects when a very small fraction of the tumor cells express the gene? Finally can transfection with E. coli PNP and treatment with MeP-dR slow the growth of multifocal ovarian tumors in a mouse model that resembles the environment and biology of the human disease? The levels of bystander killing described here approximate what might reasonably be expected in vivo using currently available viral or nonviral vectors.
Results
Development of a transactivation system for high level expression of E. coli PNP in human tumor cells In order to test the bystander killing potential of cells expressing E. coli PNP, we first developed a plasmid transactivation model capable of high level expression of the gene (Figure 1 ). The expression level observed in culture by tat transactivation of an LTR driven luciferase reporter gene was approximately 100-fold greater than a conventional SV40 promoter (data not shown). Because E. coli PNP assembles as a hexamer, transactivation might be less than with luciferase, which is active as a monomer. 10, 11 Nevertheless, transactivation of E. coli PNP using this approach was also substantial. E. coli PNP expression at 24 h after transfection with the tat constructs was 947 + 76 conversion units (n = 13) versus no conversion in luciferase-transfected controls. The level of expression was approximately seven-to eight-fold higher than expression from an SV40 promoter construct at 12 days after transfection (230 versus 30 conversion units; Figure  2 ).
In vitro PNP expression and tumor cell killing
To verify that pXP-HIV-PNP plus pSV-TAT strongly express E. coli PNP in SKOV 3 cells, an in vitro cell killing experiment was performed. Cell death was prominent at day 3 and complete by day 11 when pXP-HIV-PNP/pSV-TAT was used to express the transgene (left column, Figure 2a) , whereas prominent cell death was seen only after 11 days in pSV-PNP transfected cells (middle column). Cell killing was dependent upon both the level of E. coli PNP expressed and the MeP liberated by these cells (Figure 2b and c). Cells transfected with the same amount of a tat transactivated luciferase construct and treated with MeP-dR grew normally throughout the duration of the experiment (right column, Figure 2a ).
In vivo studies
To determine the number of SKOV 3 cells in a tumor that expresses E. coli PNP mRNA, hybridization with digoxigenin-labeled antisense or sense probes was performed. In Figure 3 , sectioned tumor tissue (5 days after implantation) was analyzed for E. coli PNP mRNA and revealed specific staining (shown in red) only with the anti-sense probe. Less than one in 1000 cells expressed detectable E. coli PNP mRNA in these tumor tissues. Five days after implantation, E. coli PNP activity in SKOV 3 tumors cotransfected using pSV-TAT was 174 ± 26 CU. This was very near the level previously shown in transduced tumors to be sufficient to elicit tumor regressions following administration of MeP-dR. 4 Because of the low efficiency method used to transfect ovarian tumor cells (cationic liposomes), the present model allowed us to test whether tumors with a small fraction of cells expressing E. coli PNP would be sensitive to MeP-dR.
Antitumor effects were examined in the ovarian tumor model by two independent protocols: Direct measurements of tumor size and survival studies in SCID mice harboring human ovarian tumors in the peritoneal cavity. Mice were divided into four groups: E. coli PNP expressing tumors (with or without MeP-dR) and luciferase expressing tumors (with or without MeP-dR). Tumors transfected with luciferase had no detectable E. coli PNP activity. Average tumor burdens from the four groups of mice killed at 14 days after implantation are shown in Figure 4a . No statistically significant antitumor effects were detected due to E. coli PNP expression alone, luciferase alone, or luciferase plus MeP-dR treatment. However, MeP-dR treatment of tumors expressing E. coli PNP led to significantly smaller tumors versus control mice given E. coli PNP, but no MeP-dR (F s = 13.1; P = 0.00231). This antitumor effect was observed after only three doses of prodrug. Altering the tumor phenotype by expression of E. coli PNP also conferred an increased sensitivity in SKOV 3 tumors to MeP-dR, as judged by survival of tumor bearing animals ( Figure 4b) . The interval at which 50% lethality was observed was approximately 10 days later in the treatment group compared with the three control groups of the study, indicating an increased life span of approximately 30% for MeP-dR treated, E. coli PNP-animals (F s = 18.0; P = 0.0000793). No loss of weight or toxicity was observed as a result of a single (three-dose) cycle of MeP-dR treatment at this dosage. Because the animals in all groups in this study had pronounced involvement by peritoneal tumor at the time of death, we attributed these deaths to tumor progression. We have shown previously that the dose of prodrug used in our studies is below the maximally tolerated dose in control animals, in animals bearing PNP tumors, and in animals with tumors not expressing E. coli PNP (Ref. 4 , and data not shown).
Discussion
E. coli PNP cleaves MeP-dR to liberate a membrane permeant and freely diffusible toxin. When 20-100% of cells within a solid tumor express the E. coli PNP gene, pronounced antitumor effects and cures can be achieved in mouse models without systemic toxicity after treatment of the animals with MeP-dR. 4 These earlier studies also suggested a threshold of PNP conversion activity (approximately 200 CU) necessary to obtain antitumor effects in mice when 100% of tumor cells expressed E. coli PNP. Whether much lower percentages of cells expressing E. coli PNP might also be capable of eliciting anti-Gene Therapy a b c tumor effects is not known. For example, it has been shown in vitro that the fraction of cells expressing E. coli PNP is a much less important predictor of tumor cell killing than the overall levels of enzymatic activity within the entire tumor cell population, since both prodrug and toxin are membrane permeant. 2, 3, 5 In other words, very high level PNP expression in a small number of tumor cells might liberate enough toxin to produce measurable antitumor effects.
Figure 2 In vitro killing by E. coli PNP following MeP-dR treatment of SKOV 3 cells. (a) Cells were transfected with pXP-HIV-PNP/pSV-TAT, pSV-PNP/pSV-TAT, or LTR-driven luciferase/pSV-TAT, and treated 24 h later with 160 m MeP-dR (see Materials and methods
To test this hypothesis, we studied tumors in which high level expression was mediated through transcriptional transactivation (Figure 2) , even when the overall number of cells expressing E. coli PNP was very low (Figure 3 ). Figure 2 demonstrates that when tat transactivates the HIV-1 LTR in pXP-HIV-PNP, an entire population of cells is killed more efficiently than after transfection with pSV-PNP. This result therefore differs fundamentally from experiments with HSVtk and ganciclovir, in which per cell expression of the transgene should not influence the overall bystander killing effect based on the mechanism of action of this drug (see below). The results in Figure 2 are attributable to sevenfold greater expression of E. coli PNP by the pXP-HIV-PNP/pSV-TAT (compared with pSV-PNP) and support previous studies demonstrating that in vitro bystander killing by E. coli PNP can be explained by the levels of enzyme expressed. 1, 5 Human ovarian tumors expressing high levels of E. coli PNP were also studied after implantation into SCID mice. Mice expressing E. coli PNP in their tumors demonstrated prolonged survival and sig- nificantly less tumor tissue after treatment with MeP-dR. The experiments therefore establish that a very small fraction of tumor cells expressing the E. coli PNP gene can mediate measurable antitumor effects in a mouse model of human ovarian cancer.
The E. coli PNP gene confers potential advantages over conventional tumor sensitization genes for chemotherapy, including the herpes simplex virus thymidine kinase (HSVtk). 7, 12 The HSVtk gene phosphorylates the prodrug ganciclovir to ganciclovir monophosphate which is then converted to ganciclovir triphosphate (TP) and leads to DNA chain termination. 13 While E. coli PNP is able to kill an entire population of cells in vitro when less than 1% cells express the gene, 10-100% percent of cells must express HSVtk to elicit similar effects. 1, 5, 14 Moreover, unlike MeP, ganciclovir nucleotides are not membrane permeant and require direct cell to cell contact and/or gap junctions to mediate killing of neighboring cells. [15] [16] [17] [18] [19] Because ganciclovir-TP primarily inhibits DNA synthesis, it is less effective than MeP at killing a quiescGene Therapy
Figure 4 Intraperitoneal ovarian tumor burden at day 14 after implantation and survival of SCID mice. (a) Mice were implanted with tumors that expressed E. coli PNP or luciferase and were treated with MeP-dR (22 mg/kg body weight per injection) or vehicle on days 5, 6 and 7 after tumor implantation. On day 14, mice were killed and all grossly visible tumor tissue was removed from the peritoneal cavity and weighed. Numbers in brackets, mice per condition; error bars, s.e.m. (b) Mice were treated as in panel a, but were followed in order to determine survival. The number of mice per condition is shown in brackets.
ent (non-dividing) compartment of cells in a tumor. 6, 7 Past studies have demonstrated antitumor effects in vivo which required greater than 10% of tumor cells to express HSVtk. [20] [21] [22] 25 have further demonstrated that tumor formation in rats was retarded even without ganciclovir treatment. The requirements of a large number of transduced cells within the tumor, gap junctions, and the immune system for HSVtk/ganciclovir-mediated cell killing may limit the effectiveness of HSVtk in human trials of cancer treatment.
Recent successes using E. coli PNP in mouse models of central nervous system, liver, and prostate cancer can be analyzed in light of the biochemical information presented here. Previous in vivo studies of PNP delivery with adenovirus or vaccinia, for example, were likely to confer fractions of PNP positive cells much lower than 20%. 8, 9 Nevertheless, potent antitumor effects were observed, and might be expected based upon the strong in vivo bystander effect established by the present experiments. In addition, our experiments in ovarian tumors describe a threshold of E. coli PNP activity (170 nmoles MePdR converted per milligram tumor tissue per hour) that agrees well with previous studies 4 and can serve as a target for in vivo delivery of the enzyme. Information of this sort is not available for HSVtk or cytosine deaminase. A highly diffusible toxin may engender the risk of substantial in vivo toxicity. Importantly, we and others have been able to demonstrate complete regressions and cures in tumors transduced with E. coli PNP without substantial systemic toxicity. 4, 8, 9 The same appears to be true of the animals whose survival was improved in the present study. Finally, the present studies provide a standard for suicide gene therapy in the sense that in vivo effects are observed after three doses of prodrug (see also Figure 4 ). 4 HSVtk generally requires 5-10 days of therapy, and E. coli cytosine deaminase may call for several weeks of prodrug therapy when small fractions of tumor cells express this enzyme. 8, 26 In conclusion, the model described here was used to test in vivo bystander killing by E. coli PNP. Adenoviral, retroviral, and other vectors capable of delivering foreign genes to ovarian tumors are unlikely to transduce more than a few percent of the cells in a growing tumor mass. This same argument might also apply to other solid tumors, where consistent and efficient gene delivery has been difficult to establish both in model systems and in human trials. However, it may be possible to deliver E. coli PNP or any other gene to 0.1% of cells in a pre-established tumor. In this way, E. coli PNP might be used to sensitize human tumors to even very short courses of MeP-dR or other nucleoside prodrugs. Although the antitumor effects shown here are impressive considering that only 0.1% of the tumor cells express the E. coli PNP gene, the result is also significant because it examines an enzymatic surrogate (E. coli PNP activity) that can be used as a threshold to predict tumor responsiveness. These experiments, therefore, describe a practical and conceptual means by which bystander killing can be tested and improved upon in vitro and in vivo.
Materials and methods
In vitro cell killing of SKOV 3 cells by E. coli PNP plus MeP-dR The E. coli PNP gene was subcloned downstream of the HIV-1 LTR to create the plasmid vector pXP-HIV-PNP (Figure 1 ). Two and a half micrograms of pSV-TAT (a plasmid expressing tat RNA to transactivate the HIV-1 LTR promoter) and 2.5 g pXP-HIV-PNP were complexed with 20 g DOTAP:DOPE (1:1) cationic liposomes in OPTI-MEM (GIBCO BRL, Grand Island, NY, USA). In control experiments, a construct encoding HIV-1 LTR driving an irrelevant transgene (firefly luciferase), or a plasmid encoding an SV40 promoter regulating E. coli PNP (pSV-PNP) was substituted for pXP-HIV-PNP. The total amount of transfected DNA, the amount of pSV-TAT and the lipid:DNA ratio were held constant in all experimental and control conditions. The lipid transfection method was chosen since only a small fraction of cells (1-5%) express measurable levels of transgene by this technique. The lipid/DNA complexes were added to SKOV 3 ovarian cancer cells grown in six well trays. Four hours later, the medium was aspirated and fresh medium (10% FBS in DMEM/F12 (50/50 mix)) was added. Twenty-four hours later, MeP-dR was added at a final concentration of 160 m to the medium in some of the cultures. Cells were fixed with 4% formaldehyde at 3, 7, and 11 days after prodrug treatment for each condition and photographed.
In vivo antitumor studies Forty micrograms of pXP-HIV-PNP or the luciferase plasmid were added to 40 g pSV-TAT and complexed with 320 g DOTAP:DOPE (1:1). The lipid-DNA suspensions were added to tumor cells at 80% confluency in a T-175 flask. Growth medium containing lipid/DNA was aspirated after incubation for 4 h at 37°C and replaced with fresh medium. Twenty-four hours later, the cells were lightly trypsinized, harvested, pelleted, and resuspended in saline at 60 × 10 6 cells/ml. Thirty million tumor cells were implanted into the peritoneal cavities of female SCID mice.
Mice were treated with either vehicle or a short course of intraperitoneal MeP-dR (22 mg/kg body weight per day on days 5, 6, and 7 after tumor implantation). In mice harboring peritoneal PNP tumors, we found this to be less than the maximally tolerated dose (unpublished results). Mice in some experiments were killed at 5 days after implantation (the time at which prodrug treatment was begun) in order to formally evaluate (1) the fraction of cells expressing E. coli PNP by mRNA in situ hybridization; and (2) E. coli PNP activity in the tumors. In order to evaluate tumor burden, mice were killed on day 14 and all grossly visible peritoneal tumor was dissected and weighed. The effect of treatment with E. coli PNP and MeP-dR on survival of mice was also determined in other sets of animals. Data was analyzed using the ANOVA and orthogonal comparisons statistical methods.
PNP expression assays
Transfected tumors were excised from mice at day 5 and E. coli PNP activity was determined, as described previously.
1,4 E. coli PNP mRNA in excised tissues was also determined by fluorescence in situ hybridization (FISH). Tumors removed from mice 5 days after implantation were fixed in 4% buffered formaldehyde and sectioned on to vectabond reagent (Vector Laboratories, Burlingame, CA, USA) treated glass slides. A commercially available kit (DIG RNA Labeling Kit, Boehringer Mannheim, Mannheim, Germany) was used to generate antisense and sense probes against E. coli PNP using digoxigenin labelled nucleotide triphosphates. The antisense primer 5Ј-CAC AGC GGC CGC GTA ATA CGA CTC ACT ATA GGG TTA CTC TTT ATC GCC CAG CAG AAC GGA TTC CAG and the sense primer 5Ј-CAC AGC GGC CGC GAT TTA GGT GAC ACT ATA GAA ATG GCT ACC CCA CAC ATT AAT GCA G were used to generate single-strand DNAs that were subsequently applied to an in vitro transcription reaction to generate the labeled probes. Probes were hybridized to tissues for 12 h at 65°C in sodium chloride/sodium citrate (SSC) buffer, washed with 50% formamide/SSC buffer to remove non-bound probe, and labelled with an antidigoxigenin rhodamine conjugated monoclonal antibody (Boehringer Mannheim). Images were captured using a digital camera attached to a fluorescence microscope (Olympus, Melville, NY, USA; 615 nm emission wavelength) and then analyzed with IP Lab Spectrum Software (Signal Analytics Corporation, Fairfax, VA, USA). To determine tumor expression efficacy, we performed studies in which blinded investigators examined 10 × 1000 power magnification fields per slide and determined the number of expressing and non-expressing cells in each field. In tumor tissue slides, a typical field contained 700-800 cells. No positive cells were recorded in any field for the sense labelled experiments.
E. coli PNP enzymatic activity was measured by reverse phase HPLC as described previously. 1, 4 Briefly, cells were scraped, homogenized in 0.01 m HEPES buffer and then incubated on ice for 15 min. Samples were then sonicated for 30 s ×3, centrifuged at 100 000 g for 60 min, and dialyzed with 50 volumes of 0.1 m HEPES buffer (pH 7.4, containing 1 mm DTT and 20% glycerol). Tumor tissues were flash frozen in liquid nitrogen, and otherwise processed as above. The reaction mixtures were incubated at room temperature and aliquots were removed at 0, 0.25, 0.5, 1, 2 and 8 h. The reaction was terminated by heat denaturation at 100°C for 2 min and precipitates were removed by filtration (pore size of 0.2 m). Reverse phase high performance liquid chromotography (HPLC) was used to determine the ratio of MePdR converted by the samples (nmoles MePdR converted per milligram total protein per hour or conversion units, CU). MeP-dR and MeP were eluted from a Hypersil ODS column (Keystone Scientific, State College, PA, USA) with a solvent containing 50 mm ammonium dihydrogen phosphate and acetonitrile (19:1) at a flow rate of 1 ml/min. MeP-dR and MeP were detected by their absorbance at 254 nm and were identified by comparing their retention times and absorption spectra with authentic samples.
